Completed PHASE1 INTERVENTIONAL 5-arm NCT05713773

Pharmacodynamics and Pharmacokinetics of 3 New Developed Coated Glucose Beads in 20 Obese Healthy Subjects

Pharmacodynamics and Pharmacokinetics of 3 New Developed Coated Glucose Beads Formulations After Single-dose Administration (Fasting Conditions) in 20 Obese Healthy Subjects

Sponsor: ACC GmbH Analytical Clinical Concepts, Germany

Conditions Metabolic Syndrome Obesity

Interventions coated beads glucose (8 g) coated beads glucose (8 g) and caffeine anhydrous uncoated beads glucose (8 g) and caffeine anhydrous

Updated 4 times since 2023 Last updated: Jan 27, 2023 Started: Oct 25, 2019 Primary completion: Dec 3, 2019 Completion: Dec 3, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Metabolic Syndrome and Obesity and is currently completed. ACC GmbH Analytical Clinical Concepts, Germany leads this study, which shows 4 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2023 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Oct 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ACC GmbH Analytical Clinical Concepts, Germany
Aphaia Pharma US LLC
BioClinica, Inc.
Galephar Pharmaceutical Research (PR), Inc, Puerto Rico
Nova-Clin Medical Research Center S.R.L., Romania

Data source: Aphaia Pharma US LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Timișoara, Romania